# Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

> **NCT01000155** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia

## Interventions

- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT01000155
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study terminated early due to slow accrual.
- **Last updated:** 2017-07-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000155, "Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01000155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*